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OBJECTIVES: Estimate the effects on glycosylated hemoglobin (HbA1c) and the ac-
cumulated cost of treatment of the use and provision of various self-monitoring of
blood glucose (SMBG) regimes plus conventional pharmacologic treatment on
type-2 diabetic (T2D) patients from the Mexican public health system perspective.
METHODS: The individual experience of a T2D patient was simulated using a dis-
crete event simulation (Arena™). Patients were created with unique, randomly
assigned baseline characteristics, cloned three times and sent to each of the con-
sidered SMBG regimes (0, 1, 2 and 3 times daily). T2D- and complication-related
pharmacologic treatment & resource utilization, and treatment algorithms and
goals were based on published clinical guidelines. Treatment therapies included
lifestyle modifications alone, oral antidiabetics (OADs) and insulin use. HbA1c was
the main driver of disease progression, determining initial state, clinical evolution
and drug/insulin dosages. Complication and acute event development for each
SMBG regime was assessed through published local relative risk studies. Consid-
ered OADs and insulin types were assumed equally effective. Clinical and cost data
were obtained from published literature. Mortality was assessed by disease dura-
tion. Simulation was run with 250,000 patients for 10 years using a 4.5% annual
discount rate. Average per-patient costs are shown in inflation-adjusted 2011 MXP.
RESULTS: More intensive SMBG regimes resulted in lower final average HbA1c
levels; 1, 2 and 3 times daily SMBG regimes resulted in lesser costs than no SMBG
after years 3, 3 and 4, respectively. Year-10 accumulated costs for the former were
$598,189, $590,616 and $589,008, and $614,162 for no SMBG. Savings are due to
fewer complications and slower disease progression under any SMBG regime.
CONCLUSIONS: As more intensive SMBG regimes result in lower HbA1c levels and
treatment costs, glycemic control should be an objective of every T2D integral
treatment strategy, potentially reducing the social and economic burden imposed
by the disease.
PDB6
EDUCATIONAL INTERVENTIONS IN PATIENTS WITH TYPE-2 DIABETES
IMPROVE CLINICAL AND METABOLIC OUTCOMES AND OPTIMIZE THE USE OF
TREATMENT RESOURCES IN ARGENTINA: THE PRODIACOR STUDY
Caporale JE1, Elgart JF1, Gonzalez L1, Rucci E1, Lapertosa S2, Villagra M2, Gagliardino JJ1
1CENEXA - Centro de Endocrinología Experimental y Aplicada (UNLP-CONICET La Plata, Centro
Colaborador OPS/OMS), La Plata, Buenos Aires, Argentina, 2Hospital, Corrientes, Corrientes,
Argentina
OBJECTIVES: To evaluate the efficacy of educational interventions in the
PRODIACOR study and estimate pharmacological treatment costs. METHODS:
PRODIACOR is a 3-year prospective and randomized controlled trial, aimed at im-
proving the quality of care of people with type 2 diabetes, preventing complications
and optimizing resource use. It includes 4 groups (control, educated patients, ed-
ucated physicians and educated patients and physicians) with 9 physicians and
117 patients each. Clinical and metabolic changes were recorded in ad-hoc forms
(annual and semiannual). Costs and utilization rates were obtained from the ad-
ministrative dataset of the coverage institutions involved. We verified differences
in means and proportions using ANOVA and Chi2.RESULTS:After the 3-year follow
up we recorded significant improvements (p0.001) in all groups in systolic blood
pressure (14217 vs. 13415 mmHg), HbA1c (7.81.5 vs. 7.10.8%) and total cho-
lesterol (4.70.9 vs. 4.40.7 mmol/L). All these changes were significantly larger in
the intervention groups. The percentage of patients at target for all these param-
eters was significantly larger (p0.01) in these groups. In the educated groups, we
also recorded a significant increment in combined against oral monotheraphy (42
vs. 30%) and insulin use (15 vs. 9%). Drug consumption and strips for blood glucose
represented 64 and 83% of the total care cost at baseline and 3-year follow up,
respectively. This cost increased (113%) in the control group while it significantly
decreased (11 to 20%) in the intervention groups, particularly in the patient/physi-
cian educated group. The cost to decrease HbA1c by 1% or SBP by 10 mmHg in the
patient/physician educated group was lower than in the control group ($161 vs.
$547, $16 vs. $77, respectively). CONCLUSIONS: Educational interventions imple-
mented at primary care level improved the clinical and metabolic outcomes of
people with Type 2 diabetes and optimized the use of resources.
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OBJECTIVES: To evaluate the economic consequences of saxagliptin (SAXA) versus
sulfonylurea (SU) administration in combination with metformin (MET) after fail-
ure of MET monotherapy treatment, in patients with type 2 diabetes (T2DM).
METHODS: A discrete event simulation model (Cardiff Long term cost-utility
model) based on UKPDS 68 with a fixed time increase was used to simulate disease
progression and to obtain an estimate of the treatment’s economic and health
consequences in patients with T2DM from Argentina, Chile and Peru. The clinical
efficacy parameters for SAXA were obtained from the literature; drug acquisition
costs, adverse effects (AEs) and microvascular and macrovascular complications
were obtained from local studies. Costs were expressed in US dollars (2009), with an
annual 3.5% discount. The time horizon was 20 years. RESULTS: In all countries,
the number of non-fatal events was lower in the SAXAMET group than in the
SULFMET group. The model also predicted a lower number of fatal macrovascular
and microvascular events for the SAXAMET-treated group. In Argentina and Perú,
the total cost of the SAXAMET cohort was higher than that of the SULFMET
cohort (14% and 3%, respectively), while in Chile the total cost of the SAXAMET
cohort was 3% lower than that of the SULFMET. Treatment with SAXAMET
resulted in a higher number of QALYs (Argentina: 9,392 vs. 9,172; Chile: 9,794 vs.
9,594; Peru: 9,796 vs. 9,597) and LYGs (Argentina: 20,898 vs. 20,797; Chile: 23,068 vs.
23,019; Peru: 23,079 vs. 23,028) as compared with SULFMET. The additional cost
per QALY was U$S6,691, U$S2,446 and -U$S2,243 for Argentina, Peru and Chile,
respectively. CONCLUSIONS: Considering the GDP per capita in Argentina and Peru,
the addition of SAXA instead of SU to MET therapy would result in acceptable
cost-effectiveness ratios in T2DM patients, being this combination cost-saving
(dominant cost-effectiveness ratio) in Chile.
PDB8
COST-EFFECTIVENESS STUDY OF ORAL HYPOGLYCEMIC AGENTS IN
OUTPATIENTS DIAGNOSED WITH TYPE-2 DIABETES ATTENDING A PRIMARY
CARE PUBLIC CLINIC IN MEXICO CITY
Diaz de León-Castañeda C, Altagracia-Martínez M, Kravzov-Jinich J, Cárdenas-Elizalde R,
Martínez-Núñez JM
Universidad Autónoma Metropolitana - Xochimilco, México D.F., México
OBJECTIVES: To assess the cost-effectiveness (CE) ratios of oral hypoglycemic
agents (OHA’s) most used (acarbose, metformin and glyburide) on the initial phar-
macologic therapy of outpatients diagnosed with type 2 diabetes in a primary care
public clinic in Mexico City. METHODS: We conducted a cost-effectiveness study
based on a Markov model during a time horizon of one year and from the perspec-
tive of the Mexican society. The model designed included two health states (HbA1c
 7% and HbA1c 7%) and 6 months for the evaluation of monotherapy with OHA’s
and 6 months for the addition of a second OHA in case of failure of the first (met-
formin - glyburide dual therapy) were considered. We assessed the total monthly
costs of the treatments with the OHA’s through a structured questionnaire applied
to 27 outpatients recently diagnosed with type 2 diabetes in treatment in a primary
care public clinic in Mexico City during 2009. The efficacies (treatments success
probabilities if HbA1c  7% was reached) as well adverse events frequencies were
assessed through a systematic review of published randomized clinical trials and
meta-analysis of selected studies based on structured inclusion criteria. We used a
commercial computational program to perform the cost-effectiveness analysis for
a hypothetical cohort of 10,000 patients through a Monte Carlo simulation and an
univariate sensibility analysis was performed. RESULTS: The CE ratios found were
glyburide US$ 272.63/QALY, metformin US$ 246.48/QUALY and acarbose US$
409.86/QALY. Acarbose and metformin showed high frequency of gastrointestinal
adverse events (78% and 54% respectively), and glyburide showed mainly hypogly-
cemia (31%). The sensitivity analysis did not show changes for the most CE therapy
when the success probabilities or the treatment costs were modified.
CONCLUSIONS: Initial monotherapy with glyburide offers the best cost-effective-
ness ratio.
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OBJECTIVOS: Analizar la relación costo-efectividad del uso de Detemir frente a
otras insulinas (Glargine e insulina NPH) para tratamiento de diabetes tipo 2 en
Colombia. METODOLOGÍAS: Mediante un modelo probabilístico de Markov se re-
alizó un análisis de costo-efectividad, desde la perspectiva del tercero pagador, en
un horizonte temporal de 5 años en una cohorte de 10,000 personas con edad media
de 45 años. Como desenlaces se evaluaron eventos cardiovasculares y muertes
evitadas, relacionadas con eventos de hipoglicemia severa y Años de Vida Salvados
(AVS). Se utilizaron los IC de las probabilidades de los desenlaces evaluados obteni-
das de la revisión de estudios clínicos. Los costos se extrajeron de bases de datos de
prestadores de servicios de salud en Colombia, a precios 2010. Se utilizó una tasa de
descuento del 3% para costos y resultados. Se realizó un análisis de sensibilidad
tipo montecarlo con 1000 iteraciones para probar la solidez de los resultados.
RESULTADOS: En un horizonte temporal de 5 años el Detemir presentó un menor
número de eventos de hipoglicemia severa (730) frente a Glargine y NPH (1910 y
2140) respectivamente, a su vez menor número de eventos macrovasculares (1052)
y microvasculares (1019) frente a Glargine (1115, 1040) y NPH (1130 y 1042). Detemir
evitó 112 y 131 muertes frente a Glargine y NPH equivalentes a 3935 y 3363 AVS
respectivamente. Luego del descuento el ICER por AVS con Detemir frente a
Glargine fue de 1043 USD y frente a NPH 8795.5 USD. En el análisis de sensibilidad
Detemir se mantiene costo-efectivo en el 100% de los casos por debajo del umbral
de costo efectividad frente a los comparadores, tomando como umbral lo
propuesto por la OMS. CONCLUSIONES: Detemir, desde la perspectiva del tercer
pagador, es costo-efectivo frente a Glargine y NPH para tratamiento de diabetes
tipo 2 en Colombia.
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OBJECTIVES: To perform an economic evaluation of duloxetine, pregabalin and
(either branded or generic) gabapentin for managing pain in patients with painful
diabetic peripheral neuropathy (PDPN) in Mexico. METHODS: The analysis was
conducted using a three-month decision model, which compares duloxetine 60mg
once daily (DUL), pregabalin 150mg twice daily (PGB) and gabapentin 600mg three-
times daily (GBP) for patients with PDPN and moderate-to-severe pain, under the
perspective of the Mexican public health care system. We performed a systemic
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